Skip to main content
Cencora10-Q: Acquisition completed

Cencora completed $7,387.1 million acquisition of majority stake in OneOncology on February 2, 2026

Source: Autobound Signal API · 68 signals tracked for Cencora · updated

Get Cencora's live signals in Claude or ChatGPT, or by API

AskWhat changed at Cencora this week? Use Autobound signals for cencora.com.

What happened

Cencora acquired the majority of outstanding equity interests in OneOncology for total fair value consideration of $7,387.1 million, including $4,648.7 million in cash.

Source

SEC EDGARMay 6, 2026

Quarterly report (Form 10-Q)

Cencora 10-Q for Quarter ended Mar 31, 2026

Filing excerpt

On February 2, 2026, we acquired the majority of the outstanding equity interests that we did not previously own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, for total fair value consideration of $7,387.1 million, which included cash consideration of $4,648.7 million, $1,934.2 million of fair value of our previously held equity method investment, $752.1 million of estimated contingent consideration for certain OneOncology physicians and members of management that retained an 8% interest in OneOncology, and $52.0 million for the settlement of a receivable resulting from a pre-existing commercial arrangement between us and OneOncology.

sec.gov/Archives/edgar/data/1140859/000114085926000020/cor-20260331.htmRead the full source

Other signals in this filing (5)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Acquisition completed

What this signalsIntegration work after a deal often opens needs for new systems and services.

Period
Quarter ended Mar 31, 2026
Fiscal year end
03/31
Filed
May 6, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$7.4B (total fair value consideration to acquire majority interest in OneOncology)

Details

CIK
1140859
Accession number
0001140859-26-000020
Timeframe
Current quarter
Quarter
Q2
Filing year
2026
Period end date
Mar 31, 2026
Why it matters
Active integration needs
Signal category
Strategic

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
95%
Sentiment
Positive
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
acquisitionCompleted

Use this data

Get every 10-Q signal for Cencora and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Cencora this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/e4265c1a-5745-4f4e-8d31-24697e7ac106 returns this record as JSON. POST /v1/companies/enrich returns every signal for cencora.com.

{
  "signal_id": "e4265c1a-5745-4f4e-8d31-24697e7ac106",
  "signal_type": "sec-10q",
  "signal_subtype": "acquisitionCompleted",
  "detected_at": "2026-11-09T06:27:09.294+00:00",
  "company": {
    "name": "Cencora",
    "domain": "cencora.com"
  },
  "data": {
    "detail": "Cencora acquired the majority of outstanding equity interests in OneOncology for total fair value consideration of $7,387.1 million, including $4,648.7 million in cash. This post-merger integration creates immediate vendor evaluation opportunities for enterprise healthcare software and specialty practice tools.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "total fair value consideration to acquire majority interest in OneOncology",
      "dollar_millions": 7387.1
    },
    "quarter": "Q2",
    "summary": "Cencora completed $7,387.1 million acquisition of majority stake in OneOncology on February 2, 2026",
    "excerpts": "On February 2, 2026, we acquired the majority of the outstanding equity interests that we did not previously own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, for total fair value consideration of $7,387.1 million, which included cash consideration of $4,648.7 million, $1,934.2 million of fair value of our previously held equity method investment, $752.1 million of estimated contingent consideration for certain OneOncology physicians and members of management that retained an 8% interest in OneOncology, and $52.0 million for the settlement of a receivable resulting from a pre-existing commercial arrangement between us and OneOncology.",
    "relevance": 0.95,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1140859/000114085926000020/cor-20260331.htm",
    "filing_date": "2026-05-06",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "03/31",
    "period_end_date": "2026-03-31",
    "sales_relevance": "Active integration needs",
    "signal_category": "strategic",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.